Hancock Whitney Q2 profit rises as net interest income grows
Reuters2026/07/21 20:14
Overview
U.S. regional bank's Q2 net income and EPS rose yr/yr
Loans and deposits grew 2% each from prior quarter
Company repurchased 713k shares and announced One Florida Bank acquisition
Outlook
Company did not provide specific financial guidance for the current or future periods
Result Drivers
LOAN GROWTH - Loan balances rose 2% from Q1, driven by increases in commercial industrial lending, healthcare activity, and commercial real estate
DEPOSIT MIX - Deposit growth was led by higher interest-bearing transactions and savings, offset by declines in retail time and public fund deposits
NONINTEREST INCOME RECOVERY - Noninterest income increased sharply from Q1, reflecting the absence of a $98.6 mln securities portfolio restructuring loss that impacted the prior quarter
Company press release: ID:nBw6whkrka
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Adjusted Pre-provision net revenue |
|
$178.1 mln |
|
Q2 EPS |
|
$1.55 |
|
Q2 Net Income |
|
$126.96 mln |
|
Q2 Net Interest Income |
|
$293.01 mln |
|
Q2 CET1 Capital Ratio |
|
13.18% |
|
Q2 Credit Loss Allowance |
|
$13.78 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the banks peer group is "buy"
Wall Street's median 12-month price target for Hancock Whitney Corp is $81.00, about 4.8% above its July 20 closing price of $77.29
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago
Reuters Recommended Reads
July 20 - ServisFirst Bancshares Q2 EPS rises 40% on loan growth, higher net interest margin
July 21 - Atlantic Union Bankshares beats Q2 EPS estimates on loan growth
July 20 - SmartFinancial Q2 profit rises as loan growth lifts net interest income
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BioMarin files Form 3 for director Robert M. Plenge, reporting no beneficial ownership
Bioceres Crop Solutions 4Q Rev $55.9M >BIOX
Red Robin files Form 3 beneficial ownership statement for CMO Scott Hudler
Telix Pharmaceuticals Target Price Raised 2.4% to A$30.00/Share by Jefferies>TLX.AU